Development and Validation of a Computational Histology Artificial Intelligence–Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreatic Cancer

A study published in the Journal of Clinical Oncology reports the development and validation of an artificial intelligence–powered computational histology biomarker designed to guide chemotherapy selection in patients with advanced pancreatic cancer. The tool analyzes standard pathology tissue slides using AI to predict which patients are most likely to benefit from specific chemotherapy regimens, addressing a critical unmet need in a cancer with a five-year survival rate below ten percent. Pancreatic cancer currently lacks reliable predictive biomarkers for treatment selection, making this validated AI approach a potentially practice-changing advance. The biomarker's validation on independent patient cohorts, published in a top-tier oncology journal, underscores its clinical readiness and could help oncologists move toward more personalized treatment decisions for this devastating disease.